Improved survival in multiple myeloma (MM) patients after high-dose chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and novel agents has led to an increasing incidence of therapy-related hematological malignancies (t-HM), although optimal management remains unclear, particularly the role of allo...
M. Maulhardt, A. Angleitner, J. Büntzel et al.· Frontiers in Oncology· 0 citations
The data suggest that alloSCT can be effective after CART failure, with more than one-third of patients being in remission after two years, and these findings support the continued use of alloSCT in patients with aggressive lymphomas.
A. O. Saidy, B. Altmann, P. van Heteren et al.· Haematologica· 0 citations
In conclusion, axi-cel provided superior PFS and OS to patients with r/r LBCL compared with allo-HCT, primarily due to lower treatment-related mortality and improved disease control in patients with chemorefractory disease prior to cellular therapy.
M. Maulhardt, Lina J. Kolloch, G. Westhofen et al.· Clinical Lymphoma, Myeloma &...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.